The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Intercept Pharmaceuticals Inc

Nasdaq: ICPT
Last

(U.S.) $140.71

Today's change+11.41 +8.82%
Updated December 17 4:00 PM EST. Delayed by at least 15 minutes.
 

Intercept Pharmaceuticals Inc

Nasdaq: ICPT
Last

(U.S.) $140.71

Today's change+11.41 +8.82%
Updated December 17 4:00 PM EST. Delayed by at least 15 minutes.

Intercept Pharmaceuticals Inc up sharply

Intercept Pharmaceuticals Inc closed up sharply Wednesday, rallying (U.S.)$11.41 or 8.82% to (U.S.)$140.71. Over the last five days, shares are unchanged, but have gained 106.08% over the last year to date. This security has outperformed the S&P 500 by 126.49% during the last year.

Key company metrics

  • Open(U.S.) $129.64
  • Previous close(U.S.) $129.30
  • High(U.S.) $141.94
  • Low(U.S.) $129.30
  • Bid / Ask-- / --
  • YTD % change+106.08%
  • Volume592,489
  • Average volume (10-day)483,270
  • Average volume (1-month)501,928
  • Average volume (3-month)546,867
  • 52-week range(U.S.) $54.02 to (U.S.) $497.00
  • Beta--
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEG2.22×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$12.76
Updated December 17 4:00 PM EST. Delayed by at least 15 minutes.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue0000
Total other revenue--------
Total revenue0000
Gross profit--------
Total cost of revenue--------
Total operating expense37232014
Selling / general / administrative9865
Research & development27151410
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-36-22-20-14
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-3633-246-12
Income after tax-3633-246-12
Income tax, total--000
Net income-3633-246-12
Total adjustments to net income------0
Net income before extra. items-3633-246-12
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-3633-246-12
Inc. avail. to common incl. extra. items-3633-246-12
Diluted net income-3633-246-12
Dilution adjustment------0
Diluted weighted average shares21222119
Diluted EPS excluding extraordinary itemsvalue per share-1.691.51-11.94-0.64
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-1.691.51-11.94-0.64